Examining the association between exposome score for schizophrenia and functioning in schizophrenia, siblings, and healthy controls: Results from the EUGEI study

被引：23

作者：

Erzin, Gamze ^{[1
,2
]}

Pries, Lotta-Katrin ^{[2
]}

van Os, Jim ^{[2
,3
,4
]}

Fusar-Poli, Laura ^{[5
]}

Delespaul, Philippe ^{[2
,6
]}

Kenis, Gunter ^{[2
]}

Luykx, Jurjen J. ^{[3
,7
,8
]}

Lin, Bochao D. ^{[7
]}

Richards, Alexander L. ^{[9
]}

Akdede, Berna ^{[10
]}

Binbay, Tolga ^{[10
]}

Altinyazar, Vesile ^{[11
]}

Yalincetin, Berna ^{[12
]}

Gumus-Akay, Guvem ^{[13
,14
,15
]}

Cihan, Burcin ^{[16
]}

Soygur, Haldun ^{[17
]}

Ulas, Halis ^{[10
]}

Cankurtaran, Eylem Sahin ^{[10
]}

Kaymak, Semra Ulusoy ^{[18
]}

Mihaljevic, Marina M. ^{[19
,20
]}

Andric-Petrovic, Sanja ^{[19
,20
]}

Mirjanic, Tijana ^{[21
]}

Bernardo, Miguel ^{[22
,23
,24
]}

Mezquida, Gisela ^{[22
,23
,24
]}

Amoretti, Silvia ^{[22
,23
,24
]}

Bobes, Julio ^{[24
,25
,26
,27
]}

Saiz, Pilar A. ^{[24
,25
,26
,27
]}

Garcia-Portilla, Maria Paz ^{[24
,25
,26
,27
]}

Sanjuan, Julio ^{[24
,28
]}

Aguilar, Eduardo J. ^{[24
,28
]}

Santos, Jose Luis ^{[24
,29
]}

Jimenez-Lopez, Estela ^{[24
,30
]}

Arrojo, Manuel ^{[31
]}

Carracedo, Angel ^{[32
,33
]}

Lopez, Gonzalo ^{[24
,34
]}

Gonzalez-Penas, Javier ^{[24
,34
]}

Parellada, Mara ^{[24
,34
]}

Maric, Nadja P. ^{[19
,35
]}

Atbasoglu, Cem ^{[36
]}

Ucok, Alp ^{[37
]}

Alptekin, Koksal ^{[10
,12
]}

Saka, Meram Can ^{[36
]}

Arango, Celso ^{[24
,34
]}

O'Donovan, Micheal C. ^{[38
]}

Rutten, Bart P. F. ^{[2
]}

Guloksuz, Sinan ^{[2
,39
]}

机构：

[1] Univ Hlth Sci Ankara, Dept Psychiat, Diskapi Training & Res Hosp, Ankara, Turkey

[2] Maastricht Univ Med Ctr, Sch Mental Hlth & Neurosci, Dept Psychiat & Neuropsychol, Maastricht, Netherlands

[3] Trecht Univ, Univ Med Ctr Utrecht, UUMC Utrecht Brain Ctr, Dept Psychiat, Utrecht, Netherlands

[4] Kings Coll London, Inst Psychiat, Dept Psychosis Studies, London, England

[5] Univ Catania, Dept Clin & Expt Med, Psychiat Unit, Catania, Italy

[6] Mondriaan Mental Hlth, FACT, Maastricht, Netherlands

[7] Univ Utrecht, Univ Med Ctr Utrecht, UMC Utrecht Brain Ctr, Dept Translat Neurosci, Utrecht, Netherlands

[8] GGNet Mental Hlth, Apeldoorn, Netherlands

[9] Cardiff Univ, MRC Ctr Neuropsychiat Genet & Genom, Sch Med, Div Psychol Med & Clin Neurosci, Cardiff, S Glam, Wales

[10] Dokuz Eylul Univ, Fac Med, Dept Psychiat, Izmir, Turkey

[11] Adnan Menderes Univ, Fac Med, Dept Psychiat, Aydin, Turkey

[12] Dokuz Eylul Univ, Grad Sch Hlth Sci, Dept Neurosci, Izmir, Turkey

[13] Ankara Univ, Sch Med, Dept Physiol, Ankara, Turkey

[14] Ankara Univ, Brain Res Ctr, Ankara, Turkey

[15] Neurosci & Neurotechnol Ctr Excellence NOROM, Ankara, Turkey

[16] Middle East Tech Univ, Dept Psychol, Ankara, Turkey

[17] Turkish Federat Schizophrenia Assoc, Ankara, Turkey

[18] Guven Cayyolu Healthcare Campus, Ankara, Turkey

[19] Ataturk Res & Training Hosp Psychiat Clin, Ankara, Turkey

[20] Univ Belgrade, Fac Med, Belgrade, Serbia

[21] Clin Psychiat Clin Ctr Serbia, Belgrade, Serbia

[22] Special Hosp Psychiat Disorders Kovin, Kovin, Serbia

[23] Univ Barcelona, Hosp Clin Barcelona, Neurosci Inst, Barcelona Clin Schizophrenia Unit, Barcelona, Spain

[24] Inst Invest Biomed August Pi I Sunyer, Barcelona, Spain

[25] Biomed Res Networking Ctr Mental Hlth CIBERSAM, Barcelona, Spain

[26] Univ Oviedo, Sch Med, Dept Psychiat, Oviedo, Spain

[27] Inst Invest Sanitaria Principado Asturias, Oviedo, Spain

[28] Mental Hlth Serv Principado Asturias, Oviedo, Spain

[29] Univ Valencia, Hosp Clin Univ Valencia, Sch Med, Dept Psychiat, Valencia, Spain

[30] Hosp Virgen Luz, Dept Psychiat, Cuenca, Spain

[31] Univ Castilla La Mancha, Hlth & Social Res Ctr, Cuenca, Spain

[32] Complejo Hosp Univ Santiago Compostela, Inst Invest Sanitaria, Dept Psychiat, Santiago De Compostela, Spain

[33] Univ Santiago Compostela, Ctr Invest Biomed Red Enfermedades Raras CIBERER, Grp Med Genom, Santiago De Compostela, Spain

[34] Fdn Publ Galega Med Xenom SERGAS, Inst Invest Sanitaria Santiago Compostela IDIS, Santiago De Compostela, Spain

[35] Univ Complutense, Hosp Gen Univ Gregorio Maranon IiSGM, Sch Med, Inst Psychiat & Mental Hlth, Madrid, Spain

[36] Inst Mental Hlth, Belgrade, Serbia

[37] Ankara Univ, Sch Med, Dept Psychiat, Ankara, Turkey

[38] Istanbul Univ, Fac Med, Dept Psychiat, Istanbul, Turkey

[39] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06520 USA

来源：

EUROPEAN PSYCHIATRY | 2021年 / 64卷 / 01期

基金：

英国医学研究理事会;

关键词：

cannabis; childhood trauma; environment; functioning; psychosis; CANNABIS USE DISORDERS; CHILDHOOD TRAUMA; GLOBAL ASSESSMENT; GENETIC RISK; 1ST EPISODE; PSYCHOSIS; SYMPTOMS; RELIABILITY; POPULATION; VALIDATION;

D O I：

10.1192/j.eurpsy.2021.19

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

Background A cumulative environmental exposure score for schizophrenia (exposome score for schizophrenia [ES-SCZ]) may provide potential utility for risk stratification and outcome prediction. Here, we investigated whether ES-SCZ was associated with functioning in patients with schizophrenia spectrum disorder, unaffected siblings, and healthy controls. Methods This cross-sectional sample consisted of 1,261 patients, 1,282 unaffected siblings, and 1,525 healthy controls. The Global Assessment of Functioning (GAF) scale was used to assess functioning. ES-SCZ was calculated based on our previously validated method. The association between ES-SCZ and the GAF dimensions (symptom and disability) was analyzed by applying regression models in each group (patients, siblings, and controls). Additional models included polygenic risk score for schizophrenia (PRS-SCZ) as a covariate. Results ES-SCZ was associated with the GAF dimensions in patients (symptom: B = -1.53, p-value = 0.001; disability: B = -1.44, p-value = 0.001), siblings (symptom: B = -3.07, p-value B = -2.52, p-value < 0.001), and healthy controls (symptom: B = -1.50, p-value B = -1.31, p-value < 0.001). The results remained the same after adjusting for PRS-SCZ. The degree of associations of ES-SCZ with both symptom and disability dimensions were higher in unaffected siblings than in patients and controls. By analyzing an independent dataset (the Genetic Risk and Outcome of Psychosis study), we replicated the results observed in the patient group. Conclusions Our findings suggest that ES-SCZ shows promise for enhancing risk prediction and stratification in research practice. From a clinical perspective, ES-SCZ may aid in efforts of clinical characterization, operationalizing transdiagnostic clinical staging models, and personalizing clinical management.

引用

页数：10

共 62 条

[61] Schizophrenia Polygenic Risk Score as a Predictor of Antipsychotic Efficacy in First-Episode Psychosis [J].